| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514106000 | P-O-P or P-S-P containing (e.g., anhydrides, etc.) | 11 |
| 20090023686 | METHODS FOR THE PREPARATION AND USE OF FERRIC PYROPHOSPHATE CITRATE CHELATE COMPOSITIONS - A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts. | 01-22-2009 |
| 20090042838 | PHOSPHAPLATINS AND THEIR USE IN THE TREATMENT OF CANCERS RESISTANT TO CISPLATIN AND CARBOPLATIN - The present invention provides phosphaplatins, stable isolated monomeric phosphate complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes-unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents-do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art. | 02-12-2009 |
| 20090306017 | Methods and compositions for modulation of innate immunity - The present invention is directed towards a method of modulation of the innate immune of an organism system with the phosphorylated polyprenols of the present invention. The present invention is also directed towards a method of activation and/or modulation of the Toll-like Receptors with the phosphorylated polyprenols of the present invention. The present invention is also directed towards compound(s) comprising C35-C90 polyisoprenyls of Formula 1 and Formula 2 and their derivatives as well as methods of use of including activation and/or modulation of TLRs including TLR-2 and TLR-4 receptors and uses thereof including, e.g., use as antimicrobial, immunoregulatory, anti-cancer, cancer, for control of inflammatory conditions and as vaccine adjuvants. | 12-10-2009 |
| 20100323990 | SHIP 1 MODULATOR PRODRUGS - The present invention provides the use of prodrugs of pelorol and homopelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions. | 12-23-2010 |
| 20110092465 | MONOMERIC PYROPHOSPHATE COMPLEXES AND METHODS OF TREATMENT USING THE COMPLEXES - The present invention involves pyrophosphate bridged coordination complexes and the treatment of medical conditions, such as cancer, using the pyrophosphate bridged coordination complexes. The pyrophosphate bridged coordination complexes include four new compounds, [Co(phen) | 04-21-2011 |
| 20110112054 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells - The present invention describes organophosphorus compounds of general formula (I) | 05-12-2011 |
| 20110178043 | Inhibitors of the mevalonate pathway of streptococcus pneumoniae - Compounds and related methods as can be used for selective mevalonate pathway inhibitors. | 07-21-2011 |
| 20120178719 | MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS - The present invention relates to methods of treating neurodegenerative diseases comprising administering, to a subject in need of such treatment, one or more agent that inhibits or reduces the action, including the catalytic activity, of an enzyme of the phospholipase D family, such as phospholipase D1 and/or phospholipase D2. The present invention also relates to cell-based assays which may be used to identify agents that inhibit or reduce the activity of enzymes of the phospholipase D family and that may be used in the treatment of neurodegenerative diseases. | 07-12-2012 |
| 20130237503 | PHOSPHAPLATINS AND THEIR USE IN THE TREATMENT OF CANCERS RESISTANT TO CISPLATIN AND CARBOPLATIN - The present invention provides pharmaceutical compositions comprising phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV). In some embodiments, such compositions may be useful for treating cancers, including cisplatin- and carboplatin-resistant cancers. The provided phosphaplatin complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum agents that have a different molecular target than those in the art. | 09-12-2013 |
| 20150025041 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS - Disclosed are methods of treating viral infections comprising, in one aspect, administering compounds that are phospholipase D inhibitors. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to antiviral therapies. For example, compounds having Phospholipase D activity (e.g., isoform selective Phospholipase D inhibitors) can be useful in antiviral therapies (e.g., influenza treatments). | 01-22-2015 |
| 20160143927 | Compounds, Methods, and Treatments for Abnormal Signaling Pathways for Prenatal and Postnatal Development - The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function. | 05-26-2016 |
